Genentech (DNA-N) Stock Predictions - Stockchase
WATCH LIST
6
Genentech (DNA-N)

ON STOCKCHASE SINCE Aug 2001

biotechnology/pharmaceutical

Genentech

DNA-N

0 watching          
Join the Discussion

Genentech (DNA-N) SAVE Dec, 31, 1969, 7:00 pm

0.00 0 (100%)

This company is not ACTIVE.

What the experts are saying about DNA-N



  • All
  • Filtered
Signal Opinion Expert
HOLD
Genentech(DNA-N) 

July 21, 2008

Once a takeover bid comes in, it no longer trades on fundamentals. If you already own, keep the stock and wait to see what happens. You could take a bit of profit here.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Once a takeover bid comes in, it no longer trades on fundamentals. If you already own, keep the stock and wait to see what happens. You could take a bit of profit here.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$93.880
Owned Owned
Unknown

DON'T BUY
Genentech(DNA-N) 

June 21, 2007

The model price is $48.70, a negative 35% differential. Would choose Amgen (AMGN-Q), which he owns.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The model price is $48.70, a negative 35% differential. Would choose Amgen (AMGN-Q), which he owns.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$75.970
Owned Owned
No

DON'T BUY
Genentech(DNA-N) 

June 7, 2007

One of the largest bio-tech firms in the world. He thinks there is not enough control, in knowing how research is going to be able to proceed. (phase 1 through phase 6). Instead he uses PBE-A which is a portfolio. Less exciting but more rewarding long term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
One of the largest bio-tech firms in the world. He thinks there is not enough control, in knowing how research is going to be able to proceed. (phase 1 through phase 6). Instead he uses PBE-A which is a portfolio. Less exciting but more rewarding long term.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Charles Lannon

Director o, Toron Investment Man...

Price Price
$74.901
Owned Owned
No

BUY
Genentech(DNA-N) 

July 13, 2005

The biotech sector is one of the first growth oriented groups that turned up and has been relatively strong all year. Likes this one because it has a diversified revenue line. Growing cash flow.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The biotech sector is one of the first growth oriented groups that turned up and has been relatively strong all year. Likes this one because it has a diversified revenue line. Growing cash flow.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$86.650
Owned Owned
Yes

DON'T BUY
Genentech(DNA-N) 

May 24, 2005

Model price is $25.24. Very expensive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Model price is $25.24. Very expensive.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$78.600
Owned Owned
No

TOP PICK
Genentech(DNA-N) 

August 29, 2001

Growing revenue profits annually 25%. Good products. Good value at this price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Growing revenue profits annually 25%. Good products. Good value at this price.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Sinkins, C

Senior Por, Sentry Select Capita...

Price Price
$47.250
Owned Owned
Unknown

Showing 1 to 6 of 6 entries
Successfully Saved Company
Successfully Saved Company
1+
JOIN THE DISCUSSION
1 comments in the last 7 days